Mostrar el registro sencillo del ítem

dc.contributor.author
González Rubio, Sandra  
dc.contributor.author
López Sánchez, Laura  
dc.contributor.author
Muñoz Castañeda, Juan  
dc.contributor.author
Linares, Clara I.  
dc.contributor.author
Aguilar Melero, Patricia  
dc.contributor.author
Rodríguez Perálvarez, Manuel  
dc.contributor.author
Sánchez Sánchez, Rafael  
dc.contributor.author
Fernández Alvarez, Ana Julia  
dc.contributor.author
Casado, Marta  
dc.contributor.author
Montero Álvarez, Jose L.  
dc.contributor.author
Rodríguez Ariza, Antonio  
dc.contributor.author
Muntané, Jordi  
dc.contributor.author
de la Mata, Manuel  
dc.contributor.author
Ferrín, Gustavo  
dc.date.available
2019-09-25T20:08:19Z  
dc.date.issued
2015-03  
dc.identifier.citation
González Rubio, Sandra; López Sánchez, Laura; Muñoz Castañeda, Juan; Linares, Clara I.; Aguilar Melero, Patricia; et al.; GCDCA down-regulates gene expression by increasing Sp1 binding to the NOS-3 promoter in an oxidative stress dependent manner; Pergamon-Elsevier Science Ltd; Biochemical Pharmacology; 96; 3-2015; 39-51  
dc.identifier.issn
0006-2952  
dc.identifier.uri
http://hdl.handle.net/11336/84463  
dc.description.abstract
During the course of cholestatic liver diseases, the toxic effect of bile acids accumulation has been related to the decreased expression of endothelial nitric oxide synthase (NOS-3) and cellular oxidative stress increase. In the present study, we have investigated the relationship between these two biological events. In the human hepatocarcinoma cell line HepG2, cytotoxic response to GCDCA was characterized by the reduced activity of the respiratory complexes II. +. III, the increased expression and activation of the transcription factor Sp1, and a higher binding capacity of this at positions -1386, -632 and -104 of the NOS-3 promoter (pNOS-3). This was associated with a decreased promoter activity and a consequent reduction of NOS-3 expression. The use of antioxidants in GCDCA-treated cells caused a lower activation of Sp1 and the recovery of the pNOS-3 activity and NOS-3 expression and activity. Similarly, the specific inhibition of Sp1 resulted in the improvement of NOS-3 expression. Both, antioxidant treatment and Sp1 inhibition were associated with the reduction of cell death-related parameters. Bile duct ligation in rats confirmed in vitro results concerning the activation of Sp1 and the reduction of NOS-3 expression. Our results provide direct evidence for the involvement of Sp1 in the regulation of NOS-3 expression during cholestasis. Thus, the identification of Sp1 as a potential negative regulator of NOS-3 expression represents a new mechanism by which the accumulation of bile acids causes a cytotoxic effect through the oxidative stress increase, and provides a new potential target in cholestatic liver diseases.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Pergamon-Elsevier Science Ltd  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/  
dc.subject
CHOLESTATIC LIVER DISEASE  
dc.subject
ENDOTHELIAL NITRIC OXIDE SYNTHASE  
dc.subject
GLYCOCHENODEOXYCHOLIC ACID  
dc.subject
OXIDATIVE STRESS  
dc.subject
TRANSCRIPTION FACTOR SP1  
dc.subject.classification
Bioquímica y Biología Molecular  
dc.subject.classification
Ciencias Biológicas  
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS  
dc.title
GCDCA down-regulates gene expression by increasing Sp1 binding to the NOS-3 promoter in an oxidative stress dependent manner  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2019-05-10T14:09:15Z  
dc.journal.volume
96  
dc.journal.pagination
39-51  
dc.journal.pais
Estados Unidos  
dc.description.fil
Fil: González Rubio, Sandra. Universidad de Córdoba; España  
dc.description.fil
Fil: López Sánchez, Laura. Universidad de Córdoba; España. Universidad Carlos III de Madrid. Instituto de Salud; España  
dc.description.fil
Fil: Muñoz Castañeda, Juan. Universidad de Córdoba; España  
dc.description.fil
Fil: Linares, Clara I.. Universidad de Córdoba; España  
dc.description.fil
Fil: Aguilar Melero, Patricia. Universidad de Córdoba; España  
dc.description.fil
Fil: Rodríguez Perálvarez, Manuel. Universidad de Córdoba; España. Universidad Carlos III de Madrid. Instituto de Salud; España  
dc.description.fil
Fil: Sánchez Sánchez, Rafael. Reina Sofia University Hospital; España  
dc.description.fil
Fil: Fernández Alvarez, Ana Julia. Biomedicine Institute of Valencia; España. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Casado, Marta. Universidad Carlos III de Madrid. Instituto de Salud; España  
dc.description.fil
Fil: Montero Álvarez, Jose L.. Universidad de Córdoba; España. Universidad Carlos III de Madrid. Instituto de Salud; España  
dc.description.fil
Fil: Rodríguez Ariza, Antonio. Universidad de Córdoba; España. Universidad Carlos III de Madrid. Instituto de Salud; España  
dc.description.fil
Fil: Muntané, Jordi. Universidad de Córdoba; España. Universidad Carlos III de Madrid. Instituto de Salud; España  
dc.description.fil
Fil: de la Mata, Manuel. Universidad de Córdoba; España. Universidad Carlos III de Madrid. Instituto de Salud; España. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Ferrín, Gustavo. Universidad de Córdoba; España. Universidad Carlos III de Madrid. Instituto de Salud; España  
dc.journal.title
Biochemical Pharmacology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.bcp.2015.04.017  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0006295215002403